Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity’s impact on clinical outcomes in biologic-treated patients with ulcerative colitis (UC) is inconsistent. Hence, we evaluated the impact of obesity on response to biologic therapy in UC patients.